MedTrace Logo

Impact of Exenatide on Sleep Duration

NCT01416649 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2023-04-26

No results posted yet for this study

Summary

This study investigates the effect of exenatide, a FDA approved medication for the treatment of type 2 diabetes on sleep duration and quality. Individuals with type 2 diabetes will be studied before and during treatment with Exenatide.

Enrolled individuals will be asked to come to the University of Chicago for 3-4 outpatient visits over the course of 3-4 months.

Conditions

Interventions

DRUG

Exenatide

Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Silvana Pannain, MD · University of Chicago

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-01
Primary Completion
2021-04-21
Completion
2021-04-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01416649 on ClinicalTrials.gov